Maxim Group Begins Coverage on Polaryx Therapeutics (NASDAQ:PLYX)
Maxim Group began coverage on Polaryx Therapeutics in a report on Friday. They set a "buy" rating and a $10.00 price objective on the stock...
MarketBeat·22h ago
Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 15.2% - Here's Why
Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 15.2% - Here's Why...
MarketBeat·1d ago
What's Going On With Polaryx Therapeutics Stock Wednesday?
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.read more...
Benzinga·10d ago
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans
Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders.read more...